Literature DB >> 27904098

Relationship between PK/PD of Cefepime and Clinical Outcome in Febrile Neutropenic Patients with Normal Renal Function.

Yoshiko Yamashita1, Hidekazu Kamiyama, Asuka Yamamoto, Hiroki Kanoh, Yoshimitsu Yuhki, Akira Ueda, Yukari Kawamoto, Yoshikazu Gotoh, Satoshi Yamamoto.   

Abstract

The efficacy of cefepime (CFPM) is known to depend on the ratio of the time that the serum levels exceed the minimum inhibitory concentration (MIC) to the dosing interval (%T>MIC). The objective of this study was to clarify the relation between %T>MIC and clinical outcome of CFPM, and to identify the optimal dosage regimen. We investigated the outcome of CFPM treatment for febrile neutropenia (FN) patients with normal renal function. Treatment success was defined as the completion of FN therapy with CFPM only. And we calculated %T>MIC for each case based on population pharmacokinetic parameters. The MIC value for simulation was set as 8 μg/mL. In logistic regression analysis, treatment success was significantly associated with the elevation of %T>MIC in the group with persistent neutropenia, yielding a receiver operating characteristic curve with an optimal cutoff value of 73.1%. Next, we simulated %T>MIC for each case under various dosing regimens. For patients whose creatinine clearance (CLcr) exceeded 100 mL/min, it was found to be difficult to attain the objective under the current regimen. In contrast, it was calculated that treatment with 2 g three times a day (t.i.d.) could attain the objective for most of the patients with 3 h of infusion. These results suggest that CFPM treatment under the current regimen is ineffective for FN patients with normal or augmented renal function, and that 2 g t.i.d. is necessary in quite a lot cases, although such use is off-label.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27904098     DOI: 10.1248/yakushi.16-00168

Source DB:  PubMed          Journal:  Yakugaku Zasshi        ISSN: 0031-6903            Impact factor:   0.302


  2 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.

Authors:  Gwendolyn M Pais; Jack Chang; Erin F Barreto; Gideon Stitt; Kevin J Downes; Mohammad H Alshaer; Emily Lesnicki; Vaidehi Panchal; Maria Bruzzone; Argyle V Bumanglag; Sara N Burke; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2022-06-29       Impact factor: 5.577

2.  Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime.

Authors:  Jiajun Liu; Michael Neely; Jeffrey Lipman; Fekade Sime; Jason A Roberts; Patrick J Kiel; Sean N Avedissian; Nathaniel J Rhodes; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2020-08       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.